See more : Vrundavan Plantation Limited (VPL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Elevation Oncology, Inc. (ELEV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Elevation Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hangzhou Coco Healthcare Products Co.,Ltd. (301009.SZ) Income Statement Analysis – Financial Results
- Instil Bio, Inc. (TIL) Income Statement Analysis – Financial Results
- The Scotts Miracle-Gro Company (SMG) Income Statement Analysis – Financial Results
- TECO 2030 ASA (TECFF) Income Statement Analysis – Financial Results
- Ruentex Development Co.,Ltd. (9945.TW) Income Statement Analysis – Financial Results
Elevation Oncology, Inc. (ELEV)
About Elevation Oncology, Inc.
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 39.00K | 27.00K | 18.00K | 15.00K | 0.00 |
| Gross Profit | -39.00K | -27.00K | -18.00K | -15.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 25.43M | 78.72M | 23.60M | 15.48M | 5.34M |
| General & Administrative | 14.90M | 15.83M | 8.45M | 1.80M | 816.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 543.18K |
| SG&A | 14.90M | 15.83M | 8.45M | 1.80M | 544.00K |
| Other Expenses | 5.11M | -506.00K | 7.00K | 11.00K | 0.00 |
| Operating Expenses | 45.45M | 94.55M | 32.05M | 17.28M | 5.88M |
| Cost & Expenses | 45.45M | 94.55M | 32.05M | 17.28M | 5.88M |
| Interest Income | 3.90M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.17M | 479.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 39.00K | 27.00K | 18.00K | 15.00K | 3.57M |
| EBITDA | -41.47M | -94.52M | -32.03M | -17.25M | -5.88M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -45.45M | -94.55M | -32.05M | -17.28M | -5.88M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -229.00K | -506.00K | 7.00K | 11.00K | 0.00 |
| Income Before Tax | -45.67M | -95.06M | -32.04M | -17.27M | -5.88M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 30.00K | 25.00K | -218.56K | -191.30K | -8.82K |
| Net Income | -45.70M | -95.08M | -32.04M | -17.27M | -5.88M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.34 | -4.09 | -1.38 | -0.73 | -0.25 |
| EPS Diluted | -1.34 | -4.09 | -1.38 | -0.73 | -0.25 |
| Weighted Avg Shares Out | 34.08M | 23.27M | 23.21M | 23.76M | 23.76M |
| Weighted Avg Shares Out (Dil) | 34.08M | 23.27M | 23.21M | 23.76M | 23.76M |
Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022
Positive initial data support the potential of seribantumab to induce deep and durable benefit for patients with tumors harboring NRG1 fusions Clinical activity observed includes a 33% response rate with 2 complete responses across all tumor types harboring NRG1 fusions,...
Best Penny Stocks to Buy as May Ends? 3 to Watch Right Now
Check these penny stocks out for your watchlist The post Best Penny Stocks to Buy as May Ends? 3 to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Elevation Oncology Stock Is Rising
Elevation Oncology Inc (NASDAQ: ELEV) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track designation to seribantumab for the tumor-agnostic treatment of advanced solid tumors that harbor NRG1 gene fusions. Seribantumab.
Elevation Oncology to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
NEW YORK, Nov. 18, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced that members of the senior management team will present...
Elevation Oncology's Seribantumab Included as Part of a Case Series Presentation at the Australasian Gastro-Intestinal Trials Group 2021 Annual Scientific Meeting
NEW YORK, Oct. 14, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced an investigator-presented case series from the Cancer Molecular Screening and...
7 Companies Go Public Today. What Investors Need to Know.
Acurx Pharmaceuticals, Alpha Teknova, Elevation Oncology, GH Research, Graphite Bio, and MissFresh are listed on the Nasdaq. Mister Car Wash is trading the New York Stock Exchange.
Elevation Oncology Announces Pricing of Initial Public Offering
NEW YORK, June 24, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced the pricing of its initial public offering of 6,250,000...
Source: https://incomestatements.info
Category: Stock Reports